3种生物制剂治疗中重度克罗恩病的药物经济学评价
x

请在关注微信后,向客服人员索取文件
| 篇名: | 3种生物制剂治疗中重度克罗恩病的药物经济学评价 |
| TITLE: | Pharmacoeconomic evaluation of three biologic agents in the treatment of moderate-to-severe Crohn’s disease |
| 摘要: | 目的 从中国卫生体系角度,评价乌司奴单抗、维得利珠单抗与英夫利西单抗3种生物制剂治疗中重度克罗恩病(CD)的经济性,为临床决策与医保基金的精细化管理提供证据。方法基于TreeAgePro2019软件构建决策树-马尔可夫混合模型,其中诱导期采用6周决策树模型,维持期采用为期5年的马尔可夫状态转移模型(周期长度为8周)。模型健康状态包括疾病缓解、轻度疾病、中重度疾病、手术及死亡。临床疗效参数源自UNITI/IM-UNITI、GEMINI、ACCENTⅠ等关键Ⅲ期随机对照试验及荟萃分析;成本参数涵盖药品成本、给药管理费、健康状态管理成本及不良反应处理成本等;健康产出以质量调整生命年(QALY)表示;成本与效用值采用4.5%的年折现率进行折现。意愿支付(WTP)阈值设定为2倍中国2025年人均国内生产总值(199330元/QALY)。通过基础分析计算各方案总成本、总效用及增量成本-效果比(ICER),采用单因素敏感性分析与概率敏感性分析验证模型稳健性。结果基础分析结果显示,英夫利西单抗、维得利珠单抗方案与乌司奴单抗方案的总成本分别为383933.60、343887.11、364862.00元,健康收益分别为2.57、2.91、3.04QALYs。以英夫利西单抗方案为参照,维得利珠单抗方案与乌司奴单抗方案的成本更低、健康收益更高,均具有绝对优势;以维得利珠单抗方案为参照,乌司奴单抗方案的ICER为150952.23元/QALY,低于本研究的WTP阈值,后者更具有经济性。单因素敏感性分析结果表明,药品价格、维持期状态转移概率及缓解状态效用值为影响ICER的关键参数。概率敏感性分析结果显示,在本研究WTP阈值下,乌司奴单抗方案对比英夫利西单抗方案与维得利珠单抗方案具有经济性的概率分别为90.0%和58.8%。结论在当前价格体系下,针对中国中重度CD患者,相较于英夫利西单抗方案,乌司奴单抗方案与维得利珠单抗方案在经济性上均具有绝对优势;而乌司奴单抗方案相较于维得利珠单抗方案更具有经济性。 |
| ABSTRACT: | OBJECTIVE To evaluate the cost-effectiveness of three biologic agents-ustekinumab, vedolizumab, and infliximab-in the treatment of moderate-to-severe Crohn’s disease (CD) from the perspective of the Chinese healthcare system, providing evidence for clinical decision-making and refined management of healthcare insurance funds.METHODS A decision tree-Markov hybrid model was constructed using TreeAge Pro 2019 software. A 6-week decision tree model was used for the induction phase, followed by a 5-year Markov state-transition model (cycle length: 8 weeks) for the maintenance phase. Health states included remission, mild disease, moderate-to-severe disease, surgery, and death. Clinical efficacy parameters were derived from key Phase Ⅲ randomized controlled trials and meta-analyses, including UNITI/IM-UNITI, GEMINI, and ACCENT Ⅰ. Cost parameters encompassed drug costs, administration costs, health-state management costs, and adverse event management costs, etc. Health outcomes were expressed as quality-adjusted life year (QALY). Costs and utility values were discounted at an annual rate of 4.5%. The willingness-to-pay (WTP) threshold was set at twice the 2025 Chinese gross domestic product per capita (199 330 yuan/QALY). Base-case analysis was performed to calculate total costs, total utilities, and incremental cost-effectiveness ratio (ICER). Model robustness was validated through one-way sensitivity analysis and probabilistic sensitivity analysis.RESULTS In the base-case analysis, the total costs of the infliximab, vedolizumab, and ustekinumab regimens were 383 933.60, 343 887.11, and 364 862.00 yuan, respectively, with health gains of 2.57, 2.91, and 3.04 QALYs. Using the infliximab regimen as the reference, vedolizumab and ustekinumab regimens were both associated with lower costs and higher health benefits, both showing absolute dominance. Using the vedolizumab regimen as the reference, the ICER of the ustekinumab regimen was 150 952.23 yuan/QALY, which was below the WTP threshold of this study, indicating greater cost-effectiveness. One-way sensitivity analysis showed that drug prices, maintenance-phase transition probabilities, and remission-state utility values were key parameters affecting the ICER. Probabilistic sensitivity analysis showed that, at the WTP threshold of this study, the probabilities of the ustekinumab regimen being cost-effective compared with the infliximab regimen and vedolizumab regimen were 90.0% and 58.8%, respectively.CONCLUSIONS Under the current pricing system, for Chinese patients with moderate-to-severe CD, compared with the infliximab regimen, both the ustekinumab and vedolizumab regimens have absolute dominance; moreover, ustekinumab regimen has a greater cost-effectiveness than vedolizumab regimen. |
| 期刊: | 2026年第37卷第21期 |
| 作者: | 任林;郁文刘;王新春;陈蓉 |
| AUTHORS: | REN Lin,YU Wenliu,WANG Xinchun,CHEN Rong |
| 关键字: | 克罗恩病;药物经济学;乌司奴单抗;维得利珠单抗;英夫利西单抗;生物制剂;决策树-马尔可夫混合模型 |
| KEYWORDS: | Crohn’s disease;Pharmacoeconomics;ustekinumab;vedolizumab;Infliximab;biologic agents;decision tree-Markov hybrid model |
| 阅读数: | 2 次 |
| 本月下载数: | 0 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!
返回
加入收藏










